SB525334
SB525334 structure
|
Common Name | SB525334 | ||
|---|---|---|---|---|
| CAS Number | 356559-20-1 | Molecular Weight | 343.425 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 540.5±45.0 °C at 760 mmHg | |
| Molecular Formula | C21H21N5 | Melting Point | 159 °C | |
| MSDS | Chinese USA | Flash Point | 238.6±21.7 °C | |
| Symbol |
GHS06 |
Signal Word | Danger | |
|
Mesenchymal activin-A overcomes defective human trisomy 21 trophoblast fusion.
Endocrinology 152 , 5017-28, (2011) Placental development is markedly abnormal in trisomy 21 (T21) pregnancies. We hypothesized that abnormal paracrine cross talk between the fetal mesenchymal core and the trophoblast might be involved in the defect of syncytiotrophoblast formation and function... |
|
|
Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
J. Pharmacol. Exp. Ther. 313 , 943-951, (2005) SB-525334 (6-[2-tert-butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline) has been characterized as a potent and selective inhibitor of the transforming growth factor-beta1 (TGF-beta1) receptor, activin receptor-like kinase (ALK5). The compound inhi... |
|
|
Activin-Like Kinase 5 (ALK5) Mediates Abnormal Proliferation of Vascular Smooth Muscle Cells from Patients with Familial Pulmonary Arterial Hypertension and Is Involved in the Progression of Experimental Pulmonary Arterial Hypertension Induced by Monocrotaline
Am. J. Pathol. 174(2) , 380-9, (2009) Mutations in the gene for the transforming growth factor (TGF)-β superfamily receptor, bone morphogenetic protein receptor II, underlie heritable forms of pulmonary arterial hypertension (PAH). Aberrant signaling via TGF-β receptor I/activin receptor-like kin... |
|
|
Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats.
Clin. Cancer Res. 13 , 3087-3099, (2007) Transforming growth factor beta (TGF-beta), which generally stimulates the growth of mesenchymally derived cells but inhibits the growth of epithelial cells, has been proposed as a possible target for cancer therapy. However, concerns have been raised that wh... |
|
|
Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.
Exp. Mol. Pathol. 83 , 39-46, (2007) Activin receptor-like kinase 5 (ALK5) is a type I receptor of transforming growth factor (TGF)-beta. ALK5 inhibition has been reported to attenuate the tissue fibrosis including pulmonary fibrosis, renal fibrosis and liver fibrosis. To elucidate the inhibitor... |